2025国谈第三日下午：诺华、罗氏、贝达药业等企业代表入场

Core Viewpoint - The 2025 National Medical Insurance Directory negotiations are ongoing, focusing on pricing discussions for innovative drugs, particularly in the chronic disease medication sector [1] Group 1: Negotiation Details - The third day of the national negotiations began at approximately 1:40 PM, with participation from companies such as Novartis, Gensai, Roche, and Betta Pharmaceuticals [1] - The morning session emphasized negotiations on chronic disease medications, with Eli Lilly and Sinopharm bringing significant products to the discussions [1]